老年医保患者TAVI术后瓣膜再干预的趋势与结局
基于Medicare数据库324,701例2013-2022年接受TAVI的患者,分析瓣膜再干预趋势及结局。再干预数量从2013年49例增至2022年505例(APC 22.1%),TAVI-in-TAVI和外科取出均增加,但再干预后死亡和心衰住院风险随时间下降。
要点
- TAVI后再干预数量显著增加,2022年达505例,APC 22.1%。
- 再干预后30天死亡率8.7%,1年死亡率18.7%。
- 调整后死亡风险(HR 0.96)和心衰住院风险(sHR 0.87)随时间下降。
核心结论
- TAVI后再干预数量增加,但相关死亡和心衰住院风险下降,反映老年失败TAVI管理改善。
研究设计与样本
- 基于Medicare数据库的回顾性队列研究,纳入2013-2022年324,701例TAVI患者,分析再干预趋势和结局。
主要发现
- 2013-2022年共2387例TAVI后瓣膜再干预,其中TAVI-in-TAVI占61.3%,外科主动脉瓣置换占38.7%。
- 再干预数量从2013年49例增至2022年505例,APC 22.1%(P < .001)。
- TAVI-in-TAVI发生率2013-2019年APC -27.6%,2019-2022年APC 35.2%。
- 外科取出率至2017年不变,之后APC 18.3%(P < .001)。
- 再干预后30天死亡率8.7%,1年死亡率18.7%;调整后死亡风险HR 0.96(95% CI 0.93-0.99,P = .01),心衰住院sHR 0.87(95% CI 0.83-0.91,P < .001)随时间下降。
临床怎么用
- TAVI术后再干预需求增加,应关注失败TAVI的识别和再干预时机。
- 再干预结局随时间改善,支持对老年患者积极管理失败TAVI。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: With the growing use of transcatheter aortic valve implantation (TAVI), data on TAVI failure and outcomes after reintervention remain limited. This study describes trends in reinterventions and associated outcomes, including mortality and heart failure hospitalization in elderly patients. METHODS: Using the Medicare database, we identified 324,701 patients who underwent TAVI during 2013-2022. Trends in aortic valve reinterventions-including TAVI-in-TAVI and surgical explants-were analyzed using Joinpoint regression to report annual percent change (APC). A Cox proportional hazards model was used to estimate the association between the year of reintervention and the risk of outcomes as hazard ratios. RESULTS: Between 2013 and 2022, 2387 patients underwent aortic valve reintervention after TAVI (61.3% TAVI-in-TAVI and 38.7% surgical aortic valve replacement). The number of aortic valve reinterventions increased from 49 in 2013 to 505 in 2022 (APC: 22.1%; P < .001). There was an initial decline in the TAVI-in-TAVI incidence rate per 1000 person-years (APC: -27.6% from 2013 to 2019), followed by a significant increase (APC: 35.2% from 2019 to 2022). Meanwhile, the incidence rate remained unchanged for explant until 2017, after which it increased (APC: 18.3%; P < .001). After reintervention, 8.7% of patients died within 30 days, and 18.7% within 1 year. The adjusted risk of mortality (hazard ratio, 0.96; 95% CI, 0.93-0.99; P = .01) and heart failure hospitalization (subdistribution hazard ratio, 0.87; 95% CI, 0.83-0.91; P < .001) declined significantly over time. CONCLUSIONS: Reinterventions, mainly surgical explants, have increased after TAVI. However, associated mortality and heart failure hospitalization have declined, reflecting an improvement in the management of failed TAVI in elderly patients. Further research into rising explant rates is warranted.
引用
- Alabbadi S, Iribarne A, Egorova N, et al. Trends in aortic valve reintervention: Incidence and outcomes after failed transcatheter aortic valve implantation among patients receiving Medicare. J Thorac Cardiovasc Surg. 2026. PMID: 42162684. doi:10.1016/j.jtcvs.2026.04.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。